SCHEMBL451748

SCHEMBL451748

SCc1ccncc1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL1345387 0.97
SCHEMBL1129630 0.84 MAPT (0.55)
SCHEMBL73482 0.77
SCHEMBL6169033 0.76 RAB9A (0.46)
SCHEMBL127369 0.75 IDO1 (0.69)
Pyridine SCHEMBL27170372 0.75 IDO1 (0.50)
Hydrochloric Acid SCHEMBL258153 0.75 LOXL2 (0.54)
SCHEMBL151822 0.73 LOXL2 (0.68)
SCHEMBL721736 0.73 CYP17A1 (0.61)
SCHEMBL842668 0.73 HRH1 (0.56)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 419 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11667611-B2 Compositions and methods for inhibition of the JAK pathway RIGEL PHARMACEUTICALS, INC. (US) 2023-06-06 US claimed
WO-2023053030-A1 AN IMPROVED PROCESS FOR PURIFICATION OF PROTEIN KASHIV BIOSCIENCES, LLC (US) 2023-04-06 WO claimed
US-10556942-B2 Process for the purification of TNFR:Fc fusion protein LUPIN LIMITED (IN) 2020-02-11 US claimed
US-20170152298-A1 PROCESS FOR THE PURIFICATION OF TNFR:FC FUSION PROTEIN LUPIN LIMITED (IN) 2017-06-01 US claimed
EP-3155009-A1 PROCESS FOR THE PURIFICATION OF TNFR:FC FUSION PROTEIN Lupin Limited (IN) 2017-04-19 EP claimed
WO-2015189832-A1 PROCESS FOR THE PURIFICATION OF TNFR:FC FUSION PROTEIN LUPIN LIMITED (IN) 2015-12-17 WO claimed
CN-1918127-B New cyclocompound having 4-pyridylalkylthio group to which substituted or unsubstituted amino group is introduced SANTEN PHARMACEUTICAL CO.,LTD. (JP) 2012-02-15 CN claimed
CN-1918127-A New cyclocompound having 4-pyridylalkylthio group to which sustituted or unsubstituted amino group is introduced SANTEN PHARMACEUTICAL CO LTD (JP) 2007-02-21 CN claimed
US-6946581-B2 Bisphenol compound composition having excellent thermal stability MITSUBISHI CHEMICAL CORPORATION (JP) 2005-09-20 US claimed
US-20050113450-A1 Antibacterial agents PHARMACIA & UPJOHN COMPANY 2005-05-26 US claimed
US-5614533-A Substituted pipecolinic acid derivatives as HIV protease inhibitors BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH, INC. (CA) 1997-03-25 US claimed
US-5453438-A Hydroxamic acid based collagenase inhibitors BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) 1995-09-26 US claimed
EP-0560269-B1 Substituted pyrrolidine derivatives as HIV protease inhibitors BIO MEGA BOEHRINGER INGELHEIM (CA) 1995-05-31 EP claimed
EP-0560268-B1 Substituted pipecolinic acid derivatives as HIV protease inhibitors BIO MEGA BOEHRINGER INGELHEIM (CA) 1995-01-04 EP claimed
US-5304604-A Treating diseases involving tissue degradation, promoting wound healing BRITISH BIO-TECHNOLOGY LIMITED (GB) 1994-04-19 US claimed
WO-1993018003-A1 SUBSTITUED PIPECOLINIC ACID DERIVATIVES AS HIV PROTEASE INHIBITORS BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) 1993-09-16 WO claimed
EP-0560269-A1 Substituted pyrrolidine derivatives as HIV protease inhibitors BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) 1993-09-15 EP claimed
EP-0560268-A1 Substituted pipecolinic acid derivatives as HIV protease inhibitors BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) 1993-09-15 EP claimed
EP-0175363-B1 4,5-DIHYDRO-3(2H)-PYRIDAZINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE CASSELLA Aktiengesellschaft (DE) 1990-01-17 EP claimed
US-4816454-A CARDIOVASCULAR DISORDERS CASSELLA AKTIENGESELLSCHAFT (DE) 1989-03-28 US claimed